Think of your bone marrow as a building's plumbing system - a sprawling, intricate network of pipes carrying signals that tell blood cells when to grow, when to stop, and when to gracefully retire. Now imagine one of those pipes - let's call it FLT3 - develops a kink. Not the kind a plumber fixes with a wrench, but an internal tandem duplication (ITD for short) that essentially jams the faucet permanently open. Water everywhere. Chaos. White blood cells flooding the basement. That, in the least glamorous metaphor possible, is FLT3-ITD acute myeloid leukemia.
The Plumber Showed Up, But the Leak Kept Coming Back
About one in four AML patients carry this busted FLT3-ITD pipe, and it's bad news - higher relapse rates, worse survival, the works (Abuasab et al., 2024). We've had FLT3 inhibitors like quizartinib for a while now. Good drug. Targets the broken pipe directly. Problem is, the leukemia cells are basically the world's worst tenants: you fix one leak, they reroute the plumbing through the walls.
Remission rates with FLT3 inhibitors alone? Around 30-40%. Relapse rates? Also 30-50%. The math, as they say, isn't mathing.
Enter the Two-Wrench Approach
So a team from Hong Kong had a thought: what if we don't just shut off the broken pipe, but also cut the power to the whole building?
Quizartinib blocks the FLT3-ITD signal. Omacetaxine mepesuccinate - a mouthful derived from the Chinese plum yew tree - jams the cell's protein-making machinery right at the ribosome (Gandhi et al., 2014). Together, they're called QUIZOM, which sounds like a Marvel villain but is actually a surprisingly elegant one-two punch.
Here's the setup: quizartinib cuts the survival signals. Omacetaxine stops the cell from making replacement parts. The escalation: mitochondria start failing, misfolded proteins pile up like dirty laundry, and the cell's internal quality control just... gives up. The punchline: 83% composite complete remission in 40 patients who had already failed chemotherapy or couldn't tolerate it (Zheng et al., 2026).
Eighty-three percent. In patients nobody else could help.
The Numbers That Actually Matter
The phase II trial (NCT03135054) enrolled 40 chemo-refractory or unfit FLT3-ITD AML patients - basically the patients traditional oncology had waved a white flag on. QUIZOM delivered:
- Median leukemia-free survival: 10 months
- Median overall survival: 12.9 months
- 39% made it to bone marrow transplant - the golden ticket for long-term survival
For context, some of these patients were still alive nearly six years later. Range of overall survival: 1.8 to 69.2 months. That upper end isn't a typo.
Patients with NPM1 mutations, DNMT3A mutations, or wild-type WT1 did even better. Side effects? Mostly what you'd expect from blowing up a leukemia's supply chain - Grade 3/4 cytopenias (68%) and febrile neutropenia (60%). Not a walk in the park, but manageable for the clinical setting.
The Plot Twist: Leukemic Stem Cells Running a Side Hustle
Here's where it gets wild. Using single-cell RNA sequencing - because apparently we can now read the diary of individual cancer cells - the team discovered why some patients resist QUIZOM.
A sneaky subpopulation of leukemic stem cells had activated something called the JNK/JUN/HSPA1B axis. Their fuel? A lipid metabolism pathway driven by an enzyme called PLD1 that processes phosphatidylcholine. This little metabolic side hustle kept their protein-folding machinery running smoothly, basically weatherproofing them against the QUIZOM storm.
Three words: proteostasis. Phospholipids. Persistence.
But the callback? When researchers hit these resistant cells with a PLD1 inhibitor, it remodeled their lipid metabolism, triggered ferroptosis - a spectacular form of iron-dependent cell death - and QUIZOM started working again. The resistant cells' armor had a zipper, and now we know where it is.
Why Your Bone Marrow's Plumbing Problems Just Got More Fixable
This isn't just another incremental step. It's a roadmap. QUIZOM shows that attacking cancer from two angles simultaneously - the signaling and the protein production - works dramatically better than either alone. And the resistance mechanism they uncovered? It comes with a built-in solution.
For the roughly 25% of AML patients living with FLT3-ITD mutations, this study turns a notoriously tough subtype into something increasingly treatable. The pipes are still broken, but we're getting much better wrenches.
References:
-
Zheng, L.C., Wong, K.K.W., Lam, S.S.Y. et al. Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial. Nature Communications (2026). DOI: 10.1038/s41467-026-71186-5. PMID: 41942459
-
Abuasab, T., Herr, M.M., Giri, S. & Patel, A.B. Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review. Future Oncology 20(35) (2024). DOI: 10.1080/14796694.2024.2399425. PMID: 39297694. PMCID: PMC11572082
-
Gandhi, V., Plunkett, W. & Cortes, J.E. Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia. Clinical Cancer Research 20(7), 1735-1740 (2014). DOI: 10.1158/1078-0432.CCR-13-1707. PMID: 24501394. PMCID: PMC4048124
-
Daver, N., Venugopal, S. & Ravandi, F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer Journal 11, 104 (2021). DOI: 10.1038/s41408-021-00495-3. PMCID: PMC7697863
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.